Table 2. Treatments.
| Treatment | All (n=280), n (%) |
|---|---|
| Prior to diagnosis of BM | |
| Hormonal therapy | 103 (36.8) |
| Chemotherapy | 252 (90.0) |
| Anti-HER2 treatment | 176 (62.9) |
| Other targeted therapy | 6 (2.1) |
| After diagnosis of BM | |
| No treatment | 7 (2.5) |
| Local treatment | |
| Radiotherapya | 260 (92.9) |
| WBRT | 251 (89.6) |
| SRS or SRT | 32 (11.4) |
| Surgery | 35 (12.5) |
| Intrathecal treatment | 11 (3.9) |
| Additional systemic treatment | |
| Hormonal therapy | 34 (12.1) |
| Chemotherapy | 160 (57.1) |
| Anti-HER2 treatment | 114 (40.7) |
| Other targeted therapy | 5 (1.8) |
| Treatment combination | |
| Radiotherapya+surgery | 24 (8.6) |
| Radiotherapya+surgery+chemotherapy | 19 (6.8) |
| Radiotherapya+chemotherapy | 153 (54.6) |
| Radiotherapya+chemotherapy+anti-HER2 treatmentb | 92 (32.9) |
| Radiotherapya+Anti-HER2 treatmentb | 106 (37.9) |
| Radiotherapya+hormonal therapy+anti-HER2 treatmentb | 17 (6.1%) |
| Surgery+chemotherapy | 25 (8.9) |
Abbreviations: BM=brain metastasis; WBRT=whole brain radiotherapy; SRS=stereotactic surgery; SRT=stereotactic therapy.
a
Includes WBRT, SRS or SRT.
b
Also includes other targeted therapy.